Corcept Therapeutics has patented a method for treating Cushing’s syndrome and hormone-sensitive cancers by combining a glucocorticoid receptor modulator (GRM) like mifepristone with inhibitors like ketoconazole. The method reduces toxicity risks and allows safe administration of both drugs together, potentially improving treatment outcomes. GlobalData’s report on Corcept Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Corcept Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Corcept Therapeutics's grant share as of May 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Method of treating hyperglycemia in cushing's syndrome with mifepristone
A recently granted patent (Publication Number: US11969435B2) discloses a method for treating hyperglycemia secondary to hypercortisolism in patients with Cushing's syndrome. The method involves reducing the original once-daily oral dose of 1200 milligrams per day (mg/day) of mifepristone to an adjusted dose of 900 mg/day when the patient is concurrently receiving a strong CYP3A inhibitor. The strong CYP3A inhibitors listed in the claims include ketoconazole, itraconazole, clarithromycin, and several others.
Furthermore, the patent also covers methods for treating symptoms associated with elevated cortisol levels and endogenous Cushing's syndrome by adjusting the mifepristone dosage in patients receiving strong CYP3A inhibitors. The reduction in mifepristone dosage from 1200 mg/day to 900 mg/day is aimed at safely managing hyperglycemia secondary to hypercortisolism in patients with Cushing's syndrome. The method involves administering an initial dose of 600 mg/day followed by an adjusted dose of 900 mg/day when the patient is on a strong CYP3A inhibitor regimen. This patent provides a specific and tailored approach to address the complex treatment needs of patients with Cushing's syndrome and associated conditions.
To know more about GlobalData’s detailed insights on Corcept Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
